Medical Condition News

RSS

Exposure to phthalates increases risk of asthma-related airway inflammation in children

Children exposed to diethyl phthalate (DEP) and butylbenzyl phthalate (BBzP)-phthalate chemicals commonly found in personal care and plastic products-have elevated risk of asthma-related airway inflammation, according to researchers at Columbia Center for Children's Environmental Health (CCCEH) at the Mailman School of Public Health.

6 Sep 2012

Prenatal exposure to piperonyl butoxide increases risk of noninfectious cough in children

Children exposed in the womb to the widely used pesticide additive piperonyl butoxide (PBO) have heightened risk of noninfectious cough at ages 5 and 6, according to researchers at the Columbia Center for Children's Environmental Health (CCCEH) at the Mailman School of Public Health and of Columbia University Medical Center.

6 Sep 2012

Janssen, ImmuNext partner to develop novel cancer therapeutics

ImmuNext, Inc., today announced that it has entered into an agreement with Janssen Biotech, Inc., focused on the development of novel therapeutics that modulate the immune system for the treatment of cancer.

6 Sep 2012

UC Davis plans to open West Coast Metabolomics Center

With a $9.3 million startup grant from the National Institutes of Health, the University of California, Davis, has announced plans to open the West Coast Metabolomics Center, a high-tech consortium of research and service laboratories that will help scientists better understand and develop more effective treatments for complex diseases like diabetes, cancer and atherosclerosis.

6 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Modus Five launches Sleep Disorder: a Patient Education Multimedia Course

Modus Five has launched a new educational and user-friendly multimedia software program called Sleep Disorder: a Patient Education Multimedia Course. The software program presents helpful information by using rich graphics, interactive content, videos and animations.

6 Sep 2012

Study examines relationship between life events and survival after diagnosis of melanoma

A study that is published in the last issue of Psychotherapy and Psychosomatics examines the relationship between life events and survival after diagnosis of melanoma, a life-threatening cancer of the skin. Negative, undesirable events are important for health outcomes.

6 Sep 2012

SSM Center for Sleep Disorders, NovaSom announce first AccuSom Deliver partnership

NovaSom, Inc., the leader in home sleep testing and cost-saving solutions for Obstructive Sleep Apnea (OSA) management, announces its first AccuSom Deliver partnership with SSM Center for Sleep Disorders, a service of SSM Health Care - St. Louis, making convenient, efficient Out-of-Center Sleep Testing (OCST) available to patients at seven locations throughout the area beginning October 1, 2012.

6 Sep 2012

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Baxter International Inc. today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.

From Baxter International Inc. 6 Sep 2012

Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

A large meta-analysis conducted by researchers at Moffitt Cancer Center has concluded that breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits after treatment.

6 Sep 2012

Inexperienced psychiatrists with HCR-20-C tool more likely to predict violence risk in patients

Inexperienced psychiatrists are less likely than their veteran peers to accurately predict violence by their patients, but a simple assessment checklist might help bridge that accuracy gap, according to new research from the University of Michigan.

6 Sep 2012

Preeclampsia a significant risk factor for chronic hypertension and hospitalizations later in life

Ben-Gurion University of the Negev (BGU) researchers have determined that preeclampsia is a significant risk factor for long-term health issues, such as chronic hypertension and hospitalizations later in life.

6 Sep 2012

Out-of-pocket spending on health care in old age puts significant strain on finances

The protection of the savings of the elderly-one of the primary goals of Medicare-is under threat from a combination of spiraling healthcare costs and increased longevity. As the government attempts to reduce Medicare costs, one suggestion is that the elderly could pay a larger proportion of the costs of their healthcare. But exactly how much would this be and what impact would it have on their finances?

6 Sep 2012

Targacept plans to pursue development of TC-5214 for overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB).

6 Sep 2012

ACOEM awareness campaign helps employers identify and respond to chronic diseases

The American College of Occupational and Environmental Medicine (ACOEM) today announced a yearlong awareness-building campaign intended to help employers identify and respond to chronic diseases that commonly impact worker health and productivity.

6 Sep 2012

Patients at hospitals with longer resuscitation attempts have higher survival rates

There isn't a hard and fast rule for how long doctors should perform CPR, but new research from the University of Michigan Health System shows longer attempts might be beneficial for some patients.

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Medical Condition News

Exposure to phthalates increases risk of asthma-related airway inflammation in children

Prenatal exposure to piperonyl butoxide increases risk of noninfectious cough in children

Janssen, ImmuNext partner to develop novel cancer therapeutics

UC Davis plans to open West Coast Metabolomics Center

Sorafenib could be effective against multiple myeloma

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Modus Five launches Sleep Disorder: a Patient Education Multimedia Course

Study examines relationship between life events and survival after diagnosis of melanoma

SSM Center for Sleep Disorders, NovaSom announce first AccuSom Deliver partnership

Baxter commences anti-MIF antibody Phase I trial in malignant solid tumors

Chemotherapy increases risk of mild cognitive deficits in breast cancer patients

Inexperienced psychiatrists with HCR-20-C tool more likely to predict violence risk in patients

Preeclampsia a significant risk factor for chronic hypertension and hospitalizations later in life

Out-of-pocket spending on health care in old age puts significant strain on finances

Targacept plans to pursue development of TC-5214 for overactive bladder

ACOEM awareness campaign helps employers identify and respond to chronic diseases

Patients at hospitals with longer resuscitation attempts have higher survival rates

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News